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Available online 28 August 2013Abstract Tissue resident mesenchymal stromal cells (MSCs) contribute to tissue regeneration through various mechanisms,
including the secretion of trophic factors that act directly on epithelial stem cells to promote epithelialization. However, MSCs
in tissues constitute a heterogeneous population of stromal cells and different subtypes may have different functions. In this
study we show that CD166neg and CD166pos lung stromal cells have different proliferative and differentiative potential.
CD166neg lung stromal cells exhibit high proliferative potential with the capacity to differentiate along the lipofibroblastic and
myofibroblastic lineages, whereas CD166pos lung stromal cells have limited proliferative potential and are committed to the
myofibroblastic lineage. Moreover, we show that CD166pos lung stromal cells do not share the same epithelial-supportive
capacity as their CD166neg counterparts, which support the growth of lung epithelial stem cell (EpiSPC) colonies in vitro. In
addition, ex vivo expansion of lung stromal cells also resulted in the loss of epithelial-supportive capacity, which could be
reinstated by inhibition of the TGF-β signaling pathway. We show that epithelial-supportive capacity correlated with the level
of FGF-10 expression and the reactivation of several lung development-associated genes. In summary, these studies suggest
that TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growth in the adult lung.
© 2013 Elsevier B.V. All rights reserved.Introduction
It is well established that during development the fate and
specification of epithelial cells is mediated by paracrineAbbreviations: EpiSPC, epithelial stem/progenitor cell; MSC,
mesenchymal stromal cell; CFU-F, colony-forming unit-fibroblast;
CFU-Epi, colony-forming unit-epithelial
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mesenchyme (Nyeng et al., 2008; Shannon et al., 1998; El
Agha et al., 2012). It is now becoming increasingly evident
that this epithelial–mesenchymal interaction is also critical
for tissue regeneration in the adult lung (Warburton et al.,
2004; Holgate et al., 2000). A recent study has shown
that resident lung stromal cell progenitors accumulate in the
subepithelial space of naphthalene-injured airways (Volckaert
et al., 2011), suggesting that their recruitment is part of a
primary wound healing response. Recently, we have identified
a population of multipotent epithelial stem/progenitor cells
1223TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growth(EpiSPC) that are capable of self-renewal and give rise
to colonies of both airway and alveolar lineages in vitro
(McQualter et al., 2010; Teisanu et al., 2011). Importantly,
we have shown that the clonal proliferation of these EpiSPC
is contingent on their co-culture with primary isolated
CD45neg CD31neg Sca-1pos lung stromal cells. This suggests
that resident lung stromal cells directly regulate EpiSPC
function (McQualter et al., 2010; Teisanu et al., 2011).
However, a number of studies have shown that the lung
comprises a heterogeneous population of mesenchymal
cells, including fibroblasts, lipofibroblasts, myofibroblasts
and pericytes (McQualter et al., 2009; Summer et al., 2007;
Martin et al., 2008; Giangreco et al., 2004; Hennrick et al.,
2007). This complicates our understanding of epithelial–
mesenchymal interactions and raises the question of
whether all mesenchymal lineages share the same epithe-
lial-supportive properties. We hypothesize that the differ-
entiation of stromal cells in the local microenvironment
in lung diseases, such as excessive myofibroblast differen-
tiation in fibrosis, disrupts the normal process of re-
epithelialization. In the present study we have tested this
by analyzing the epithelial-supportive activity of lung
stromal cells by their ability to support lung EpiSPC colony
formation in vitro.Materials and methods
Mice
Female C57BL/6 mice (6–9 weeks old) were maintained in
compliance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes and provided with
food and water ad libitum.Lung cell preparations and flow cytometry
Mouse lung EpiSPC and stromal cells were prepared as
previously described with minor modifications (McQualter
et al., 2009, 2010). Briefly, upper extralobular airways were
discarded and lung lobes disaggregated by collagenase
digestion (Liberase TM; Roche; 1 Wunsch U/3 mL Hank's
buffered saline solution (HBSS)/lung for 45 min at 37 °C with
agitation) followed by hypotonic lysis of red blood cells
(10 mM KHCO3, 150 mM NH4Cl, 0.1 mM EDTA Na2 for 90 s at
RT). Single cells were then resuspended at 5 × 107 cells/mL
in HBSS plus 2% (v/v) fetal bovine serum (FBS; Invitrogen)
containing a cocktail of relevant antibodies including anti-
CD24, anti-CD29, anti-CD31, anti- CD34, anti-CD44, anti-CD45,
anti-CD49e, anti-CD51, anti-CD54, anti-CD71, anti-CD73, anti-
CD90.2, anti-CD104, anti-CD105, anti-CD106, anti-CD140a,
anti-CD166, anti-Sca-1, and anti-EpCAM and relevant isotype
controls (Biolegend). Labeled cells were washed in HBSS-2%
FBS, resuspended at 1 × 107 cells/mL and held on ice for flow
cytometric analysis and sorting. Viability was determined by
propidium iodide (PI; 1 μg/mL) staining, and doublets excluded
by forward/side scatter (height) vs. forward/side scatter
(width) gating. Intracellular αSMA staining (anti-αSMA, Sigma)
was performed using the Fix ‘n’ Perm kit (Invitrogen) according
to the manufacturer's instructions.CFU-F assay
CFU-F was assayed using a modification of our previously
described method (McCarty et al., 2009). MSCs were plated by
programming the BD Influx cell sorter to deposit 100 cells per
well (in triplicates) into 6-well flat bottom plates containing
2 mL αMEM (Invitrogen) with 10% FBS containing Insulin,
Transferrin and Selenium premix (ITS, Invitrogen), L-glutamine
(2 mM; Invitrogen), Penicillin (50 U/mL; Invitrogen) and
Streptomycin (50 μg/mL; Invitrogen). Cultures were incubat-
ed at 37 °C in a low oxygen gas phase (5% O2, 10% CO2, 85% N2)
andmediumwas replaced three times per week. After 14 days
adherent cells were fixed with 4% Paraformaldehyde for
30 min at RT and stained with Toluidine Blue (0.1% w/v;
supplier). CFU-F colonies containing at least 50 cells were
counted (colony number) and measured (colony diameter)
using a stereomicroscope (Zeiss).
Ex vivo expansion of lung stromal cells
Sorted lung stromal cells (5 × 103 cells/cm2) were plated
in 75 cm2 polypropylene flasks (Greiner) in αMEM-10% FBS
containing ITS, L-glutamine (2 mM), Penicillin (50 U/mL) and
Streptomycin (50 μg/ml). Where specified for TGF-β in-
hibition studies SB431542 (10 μM; Tocris Bioscience) or DMSO
(1/1000; Sigma) was also added to the media at 37 °C in a
low oxygen gas phase (5% O2, 10% CO2, 85% N2) and medium
was replaced three times per week. After reaching 70–80%
confluency (7 days) cells were detached by incubation with
Trypsin (0.25%; Gibco) at 37 °C for 5–10 min, washed and
reseeded in 75 cm2 polypropylene flasks at 5 × 103 cells/cm2.
Lipogenic and myogenic differentiation assays
Sorted lung stromal cells were resuspended in 100 μL
Matrigel (BD Biosciences) pre-diluted 1:1 (v/v) in αMEM-
10% FBS on a 24-well transwell filter insert (Millicell-CM;
Millipore) in a 24-well flat-bottom tissue culture plate con-
taining 400 μL of αMEM-10% FBS containing ITS, L-glutamine
(2 mM), Penicillin (50 U/mL) and Streptomycin (50 μg/mL)
plus either BMP-4 (50 ng/mL; R&D Systems) for lipofibroblast
differentiation or TGF-β1 (10 ng/mL; R&D Systems) for myo-
fibroblast differentiation. After 14 days cells were fixed with
4% Paraformaldehyde for 30 min at RT and stained with
Oil-Red O (0.35 g/L in 60% Isopropanol) or anti-αSMA con-
jugated to FITC (1:2000; Sigma). Images were taken using a
stereomicroscope.
CFU-Epi assay
Epithelial stem and progenitor cells (EpiSPC) were assayed
using a Matrigel-based clonogenic assay as previously
described (McQualter et al., 2009, 2010). Sorted EpiSPC
(5 × 103 cells/mL) were mixed with lung stromal cells
(2 × 106 cells/mL) and resuspended in 100 μL Matrigel
pre-diluted 1:1 (v/v) in αMEM-10% FCS on a 24-well transwell
filter insert (Millicell-CM) in a 24-well flat-bottom tissue
culture plate containing 400 μL αMEM-10% FBS containing
ITS, L-glutamine (2 mM), Penicillin (50 U/mL), Streptomycin
(50 μg/mL) and Heparin (0.0002%). Cultures were incubated
at 37 °C in a low oxygen gas phase (5% O2, 10% CO2, 85% N2)
and medium was replaced three times per week. Where
1224 J.L. McQualter et al.specified, BMP4 (50 ng/mL; R&D Systems) and TGF-β1
(10 ng/mL; Peprotech) were added directly to the culture
media. After 14 days, Epi-CFU colonies were counted using a
stereomicroscope.
Real time PCR
RNA was prepared using the RNAqueous-Micro RNA isolation
kit (Applied Biosystems). cDNA was prepared using the high
capacity RNA-to-cDNA kit (Applied Biosystems) and ampli-
fied (40 cycles) using TaqMan gene expression assays (Acta2-
Mm01546133, Myh11-Mm00443013 and Fgf10-Mm00433275)
and 18s RNA endogenous control according to the
manufacturer's instructions. A Ct b 40 indicates presence of
target cDNA. Data is expressed as the median fold change (2−
ddCT) ±range in gene expression.
Microarray analysis
Total RNA was purified from cultured lung stromal cells by
using Trizol (Invitrogen). RNA was treated with DNase using
the TURBO DNA-free kit (Ambion). RNA quality was assessed
with the Agilent Bioanalyzer 2100 (Agilent Technologies) by
using the Agilent RNA 6000 Nanokit (Agilent Technologies)
according to the manufacturer's protocol. RNA isolated from
MSC treated with SB431542 or DMSO was profiled on Illumina
MouseWG-6 Version 2 BeadChips at the Australian Genome
Research Facility (Melbourne), using standard Illumina pro-
tocols. Raw data was exported from BeadStudio and analyzed
using the limma package of the Bioconductor software
project. Raw intensities were normalized by using the neqc
function, which performs normexp background correction and
quantile normalization by using control probes (Ritchie et al.,
2007). Probes with low expression scorewere excluded by only
keeping the probes with detection score N0.95 in at least 3
arrays (40.5% of probes). An empirical quality weight was
estimated for each array, and the weights and the within-pool
correlation were incorporated into a linear model analysis.
Differential expression between SB431542 treated cells and
DMSO treated cells was assessed using empirical Bayes
moderated t-statistics with a false discovery rate (FDR)
of 5%. Gene ontology (GO) term enrichment analysis for
corresponding biological processes was performed using the
NIH DAVID resource (Huang da et al., 2009a, 2009b) and
functional annotation clustering with high stringency.
Statistical analysis
Significance was determined by Student's t-test using
GraphPad PRISM statistical analysis software. All data are
presented as mean ± SEM. NS = not significant.
Results
Heterogeneity of CD45neg CD31neg EpCAMneg
Sca-1pos lung stromal cells
To date the functional characterization of lung stromal cells
and their differentiated progeny has been impeded by the
paucity of specific markers that can be used to resolve
mesenchymal lineages. In this study we performed a flowcytometric analysis of MSC-associated surface markers to
characterize the heterogeneity of CD45neg CD31neg EpCAMneg
Sca-1pos lung stromal cells in the mouse lung (excluding
the upper airways). Freshly isolated lung cells were co-
stained with CD45, CD31 and EpCAM to exclude hematopoi-
etic, endothelial and epithelial cells respectively, and Sca-1
to identify lung stromal cells as previously described
(McQualter et al., 2009, 2010). The enrichment of lung
stromal cell progenitors in the Sca-1pos cell fraction was
confirmed using the colony-forming unit-fibroblast (CFU-F)
assay, which showed that CD45neg CD31neg EpCAMneg Sca-1pos
lung cells formed adherent fibroblastic cell colonies (CFU-F)
with an efficiency of 18.3 ± 2.4%, whereas Sca-1neg cells
displayed a significantly reduced CFU-F cloning efficiency of
0.78% ± 0.22 (P b 0.0001, N = 6). Analysis of the differential
expression of mesenchymal surface markers showed that
primary CD45neg CD31neg EpCAMneg Sca-1pos cells (freshly
isolated and after culture in αMEM-10% FBS in polypropylene
flasks) expressed definitive MSC markers including CD73,
CD90, and CD105 (Dominici et al., 2006) as well as MSC
associated markers such as CD29, CD44, CD49e, CD51, CD54,
CD71, CD73, CD106, CD140a and CD166 (Fig. 1). CD34, which
has traditionally been classified as a negative selection
marker for MSC, was also expressed in freshly isolated lung
stromal cells but was down-regulated after culture in αMEM-
10% FBS in polypropylene flasks (Fig. 1).
Of all the markers tested we identified CD90 and CD166 as
the onlymarkers that were able to resolvewell-defined subsets
of fresh lung stromal cells. Subsequent bivariate analysis of
CD90 versus CD166 identified phenotypically distinct CD166neg
CD90pos and CD166pos CD90neg lung stromal cells populations
(Fig. 1). We have previously shown that CD90 marks lipo-
fibroblastic lung stromal cells (McQualter et al., 2009). To
characterize the CD166pos lung stromal cell subset (Fig. 2A),
we assessed the incidence of clonal cells using the CFU-F
assay, and determined their potential for lipofibroblastic
and myofibroblastic differentiation in the presence of BMP-4
and TGF-β respectively. Lung lipofibroblast differentiation was
assessed by the staining of lipid droplets with Oil-RedO (Varisco
et al., 2012). Myofibroblast differentiation was assessed by
the expression of alpha smooth muscle actin (α-SMA), a
component of stress fibers that confers contractile properties
to myofibroblasts (Hinz et al., 2007, 2012). We show that
CD166pos cells had a significant reduction in CFU-F inci-
dence (4.67 ± 0.61%) and size (1.50 ± 0.09 cm) compared to
CD166neg cells (incidence = 21.67 ± 1.20%, size = 3.27 ±
0.09 cm; Figs. 2B–E). In addition, while CD166neg cells were
shown to differentiate into both Oil-Red Opos cells (Fig. 2F)
and α-smooth muscle actin (α-SMA)pos cells (Fig. 2H), CD166pos
cells were deficient in their ability to differentiate into Oil-Red
Opos cells (Fig. 2G) but were still able to differentiate into
α-SMApos cells (Fig. 2I). This suggests that epithelial-supportive
CD166neg cells are enriched for lung stromal cell progenitors
while non-supportive CD166pos cells are more differentiated
and committed to the myofibroblast lineage.
Differentiation of lung stromal cells represses their
epithelial-supportive capacity
Recently, using a three-dimensional colony-forming unit-
epithelial (CFU-Epi) assay, we have shown that the hetero-
geneous population of freshly isolated CD45neg CD31neg
Figure 1 Comparative analysis of MSC-related markers on fresh versus cultured lung MSC. Histograms showing the expression of
various MSC-related proteins on fresh (gray) versus ex vivo expanded (blue) lung MSC with relevant isotype controls (dotted lines).
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Figure 2 CD166 defines myofibroblast lineage commitment in lung stromal cells. A) FACS histogram of CD166 staining of freshly
isolated CD45neg CD31neg EpCAMneg Sca-1pos lung stromal cells relative to isotype control (dotted line). B) Representative images of
CFU-F from CD166neg and C) CD166pos lung stromal cells. D) Frequency and E) diameter of CFU-F from CD166neg and CD166pos lung
stromal cells (n = 12). Scatter plots show the mean of individual experimental repeats overlaid with the mean of means ± SEM.
Oil-Red O staining of lipogenic differentiation cultures from F) CD166neg and G) CD166pos lung stromal cells. αSMA staining of myogenic
differentiation cultures from H) CD166neg and I) CD166pos lung stromal cells.
1226 J.L. McQualter et al.EpCAMneg Sca-1pos lung stromal cells are necessary and
sufficient to support the proliferation and differentiation of
lung EpiSPC in vitro (McQualter et al., 2010). To determine
whether stromal cell differentiation alters their epithelial-
supportive capacity, we cultured CD166neg and CD166pos lung
stromal cells with lung EpiSPC and measured the incidence
of epithelial colony formation. We demonstrate that the
incidence of epithelial colonies supported by CD166pos
cells (4.68 ± 0.49%) was significantly reduced compared to
CD166neg cells (8.64 ± 0.31%; Fig. 3A). These data suggest
that more differentiated lung stromal cells have a reduced
epithelial-supportive capacity. To test this, we also assessed
the ability of the normally supportive CD166neg lung stromal
cells to support epithelial colony-formation in culturessupplemented with TGF-β1, which is known to promote
myofibroblast differentiation (Fig. 3B). We show that
TGF-β1 completely suppresses epithelial colony formation
(0.08 ± 0.05%) compared to untreated controls (9.24 ±
0.46%). This supports our proposal that TGF-β mediated
differentiation of lung stromal cells attenuates their epithelial-
supportive capacity. However, the suppression of epithelial
clonogenic activity in co-cultures could be due, at least in part,
to the inhibitory effect of TGF-β1 on epithelial cells.
To distinguish the contribution of epithelial versus
stromal cells, we assessed the epithelial-supportive capacity
of ex vivo expanded lung stromal cells, that were expanded
under conditions designed to promote or inhibit myo-
fibroblast differentiation prior to co-culture with EpiSPC.
Figure 3 Myofibroblast differentiation of lung stromal cells
attenuates their epithelial-supportive capacity. Colony-forming
efficiency of EpiSPC co-cultured with freshly isolated A) CD166neg
or CD166pos lung stromal cells or B) CD166neg lung stromal cells
with and without the addition of TGF-β1 (10 ng/mL).
Figure 4 Ex vivo expansion of lung stromal cells results in the
loss of their epithelial-supportive capacity. A) Colony-forming
efficiency of EpiSPC co-cultured with freshly isolated lung stromal
cells and ex vivo expanded lung stromal cells that were passaged
for 2 weeks as a monolayer culture. Scatter plot shows the mean
of individual experimental repeats overlaid with the mean of
means ± SEM. B) FACS histogram of intracellular αSMA staining of
freshly isolated (gray) and cultured (blue) Sca-1pos lung stromal
cells relative to isotype control (dotted line). C) Fold change
in gene expression of Acta2, Myh11, Fgf10 and Tgfb1 genes in
passaged cells compared to freshly isolated lung stromal cells.
Data shown as mean ± range.
1227TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growthWhen CD45neg CD31neg EpCAMneg Sca-1pos lung stromal cells
were expanded for 2 weeks in αMEM-10% FBS in polypropyl-
ene flasks prior to use in the CFU-Epi assay there was a highly
significant reduction in the incidence of EpiSPC colony
formation (1.02 ± 0.18%) compared to freshly isolated lung
stromal cells (6.86 ± 0.65%; Fig. 4A). This indicates that ex
vivo expansion of lung stromal cells results in a functional
change in their epithelial-supportive capacity. The ex-
pansion of stromal cells in vitro was associated with an
upregulation of the myofibroblast/smooth muscle differen-
tiation markers α-SMA and myosin heavy chain (Myh11) and
downregulation of fibroblast growth factor-10 (Fgf10), a
marker for lung mesenchymal progenitor cells (Figs. 4B–C).
There was no change in the expression of the TGF-β1 gene
(Tgfb1), which excludes the possibility that myofibroblast
differentiation inhibits EpiSPC proliferation through induc-
tion of TGF-β1 expression. These data suggest that primary
α-SMAneg FGF-10pos stromal cell progenitors act as EpiSPC
support cells, whereas their more differentiated α-SMApos
FGF-10neg progeny do not. These observations have broad
implications for the envisioned use of expanded MSC in
regenerative therapies, and future investigations should
examine the potential of pre-conditioning MSC with a TGF-β
inhibitor to enhance their regenerative potential. However,
excessive stimulation of EpiSPC could also increase the risk
of epithelial hyperplasia. Normal epithelial regeneration is
likely to require a balance between epithelial-supportive
and non-supportive stromal cells.Inhibition of TGF-β signaling restores the
epithelial-supportive capacity of differentiated
lung stromal cells
Given that myofibroblast differentiation is promoted by
TGF-β, we next assessed whether the epithelial-supportive
capacity of CD45neg CD31neg EpCAMneg Sca-1pos lung stromal
cells could be maintained by inhibiting the TGF-β pathway
using the TGF-β type I receptor inhibitor SB431542 (Inman et
al., 2002). As mentioned above, to set apart the potential
growth inhibitory effects of TGF-β on EpiSPC we took the
approach of pre-conditioning lung stromal cells prior to usein the CFU-Epi assay to confirm that the changes observed
were related to a direct effect on the lung stromal cells and
not the epithelium (Fig. 5A). Fig. 5 shows that ex vivo
expansion of lung stromal cells in αMEM-10% FBS plus TGF-β1
for 1 week prior to their co-culture in the CFU-Epi assay
almost completely abolished their epithelial-supportive
capacity with a significant reduction in the incidence of
EpiSPC colony formation (0.28 ± 0.06%) compared to cul-
tures with lung stromal cells grown in αMEM-10% FBS alone
(1.20 ± 0.16%). In contrast, expansion of lung stromal cells
in αMEM-10% FBS plus SB431542 for 2 weeks prior to their
co-culture in the CFU-Epi assay resulted in an EpiSPC colony
forming incidence (8.03 ± 0.55%) similar to that previously
observed with freshly isolated lung stromal cells. This data
suggests that the TGF-β signaling pathway is a key regulator
of the epithelial-supportive capacity of lung stromal cells.
To determine whether the epithelial-supportive capacity
could be restored in non-supportive stromal cells we added
SB431542 from day 7 (D7) of a 2 week culture prior to
co-culture in the CFU-Epi assay (Fig. 5B). In contrast to the
loss of epithelial support in differentiated stromal cells
cultured for 1 week in αMEM-10% FBS alone, we demonstrate
Figure 5 Inhibition of TGF-β reinstates the epithelial-supportive activity of passaged lung stromal cells. A) Schematic of
preconditioning regimen for lung stromal cells expanded in αMEM-10% FBS on polystyrene prior to use in the CFU-Epi assay.
B) Colony-forming efficiency of EpiSPC co-cultured with lung stromal cells that were expanded with/without TGF-β1 (10 ng/mL) for
1 week or with SB431542 from culture days 0 and 7 up to 2 weeks. Scatter plot shows the mean of individual experimental repeats
overlaid with the mean of means ± SEM. C) FACS histogram of intracellular αSMA staining of control (gray), and TGF-β1-treated (blue)
stromal cells at culture day 7 and SB431542-treated stromal cells at culture day 14 (Day 0–14 = blue, Day 7–14 = gray), relative to
isotype controls (dotted line). D) Fold change in gene expression of Acta2 and Fgf10 genes in TGFβ-1 and SB431542-treated stromal
cells relative to untreated control cells. Data shown as mean ± range.
1228 J.L. McQualter et al.that the incidence of EpiSPC colonies supported by lung
stromal cells supplemented with SB431542 from D7 (6.8 ±
0.43%) is restored to similar levels to that observed for
freshly isolated lung stromal cells (Fig. 5B). However, we
show that α-SMA protein (Fig. 5C) and gene expression
(Fig. 5D) were not altered in the different treatment groups,
which suggest that expression of the myofibroblast/smooth
muscle lineage marker is not functionally linked to their
epithelial-supportive capacity. Conversely, we show that
the epithelial-supportive capacity of lung stromal cells
correlates with the expression of Fgf10. We show that gene
expression of Fgf10 is upregulated in lung stromal cells after
treatment with SB431542 and downregulated after treat-
ment with TGF-β1 (Fig. 5D). These findings demonstrate
that the alternative activation of lung stromal cells with
SB431542 results in the upregulation of FGF-10 and the
restoration of their epithelial-supportive capacity. This
suggests that the epithelial supportive capacity of lung
stromal cells is regulated by TGF-β1 via the inhibition of
FGF-10 signaling.Treatment of lung stromal cells with SB431542
activates developmental signaling pathways
Given that the alternative activation of expanded lung
stromal cells with SB431542 restored their epithelial-
supportive activity, we used this model to further char-
acterize the pathways associated with changes in the
epithelial-supportive capacity of lung stromal cells. Here
we cultured CD45neg CD31neg EpCAMneg Sca-1pos lung stromal
cells in αMEM-10% FBS for 1 week and then split the passaged
cells and cultured them with or without SB431542 for the
following week. Epithelial-supportive (with SB431542) and
non-supportive (without SB431542) lung stromal cells were
then harvested for RNA isolation and a whole-genome
transcriptional analysis was performed using the Illumina
Mouse WG-6 Version 2 BeadChip.
Differential gene expression analysis revealed that 1924
genes were upregulated and 1920 genes were downregulated
in supportive lung stromal cells compared to non-supportive
lung stromal cells. To establish the functional relevance of
1229TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growththese differentially expressed (DE) genesweperformed a gene
ontology (GO) term enrichment analysis for corresponding
biological processes using the NIH DAVID resource. Subsequent
functional annotation clustering revealed an overexpression
of genes related to the activation of developmental signaling
pathways: these include gene clusters involved in blood vessel
morphogenesis, protein kinase and phosphorylation activity,
morphogenesis of an epithelium and lung development
(Fig. 6A). Conversely, there was an enrichment of genes
associatedwith cell cycling in the list of downregulated genes:
these include gene clusters involved in protein and nucleic
acid modification, cell division and programmed cell death
(Fig. 6B). A full list of GO terms associated with selected gene
clusters can be found in Table S1.
To better characterize the specific factors that influence
the supportive or non-supportive activity of lung stromal
cells we performed a secretome analysis of DE genes
encoding cytokines and growth factors, extracellular matrix
(ECM) proteins and matrix metalloproteinases that were
upregulated in supportive lung stromal cells. SeveralFigure 6 Inhibition of TGF-β in lung stromal cells reinstates a de
clusters of GO terms (for biological processes) associated with gene
lung stromal cells (expanded with SB431542) compared to non-supp
graphs show the overall enrichment score for each cluster present
modified Fisher Exact p-values in each cluster. Each cluster is label
(actual score shown within each column as DE genes/total genes inarchetypal lung embryonic mesenchyme expressed genes
associated with lung epithelial development, including
pleiotrophin, midkine, and FGF-10 were significantly in-
creased (Table 1A). There were also significant increases in
various extracellular matrix associated proteins (Table 1B),
which are amajor component of the epithelial stem cell niche,
as well as key matrix metalloproteinases (Table 1C). This data
demonstrates that the alternative activation of lung stromal
cells with SB431542 results in the upregulation of
epithelial-supportive growth factors.Discussion
In this study we provide evidence that lung stromal cells
and their differentiated progeny have different capacities
for the support of lung EpiSPC. We demonstrate that the
expression of CD166 on primary isolated lung stromal cells
correlates with a marked reduction in proliferative capacity
and a commitment to myofibroblastic differentiation. Thisvelopmental gene expression profile. Top functional annotation
s that were A) upregulated and B) downregulated in supportive
ortive lung stromal cells (expanded without SB431542). Column
ed as the geometric mean (in negative log scale) of member's
ed with the GO term of the top-scoring gene set in each cluster
list associated with the corresponding GO term).
Table 1A Cytokine and growth factor genes upregulated in supportive MSC.
Gene Name logFC Average expression Adjusted P value
Ptn Pleiotrophin 2.12 9.57 0.0001
Mdk Midkine 1.13 11.76 0.0001
Angptl4 Angiopoietin-like 4 1.20 10.87 0.0004
Igfbp4 Insulin-like growth factor binding protein 4 1.40 11.30 0.0005
Fgf10 Fibroblast growth factor 10 1.59 7.12 0.0007
Il16 Interleukin 16 1.40 5.76 0.0015
Gdf1 Growth differentiation factor 1 1.38 7.00 0.0016
Figf c-fos induced growth factor 0.94 11.94 0.0030
Bmp3 Bone morphogenetic protein 3 1.14 5.28 0.0044
Ccl27a Chemokine (C–C motif) ligand 27A 0.88 8.50 0.0068
Cxcl16 Chemokine (C–X–C motif) ligand 16 0.92 6.18 0.0103
Tgfb3 Transforming growth factor, beta 3 0.52 12.04 0.0109
Igfbp2 Insulin-like growth factor binding protein 2 0.84 9.79 0.0113
Grem1 Gremlin 1 0.46 12.31 0.0151
Ccl9 Chemokine (C–C motif) ligand 9 0.78 5.81 0.0161
Vegfb Vascular endothelial growth factor B 0.54 10.64 0.0188
Gdf10 Growth differentiation factor 10 1.03 5.76 0.0297
Tslp Thymic stromal lymphopoietin 0.69 6.27 0.0391
Igfbp3 Insulin-like growth factor binding protein 3 0.64 6.33 0.0402
Grn Granulin 0.38 12.01 0.0489
Table 1B Extracellular matrix associated genes upregulated in supportive MSC.
Gene Name logFC Average expression Adjusted P value
Fbln1 Fibulin 1 0.92 9.55 0.0018
Lgals3bp Lectin, galactoside-binding, soluble, 3 binding protein 1.17 8.81 0.0019
Agrn Agrin 0.95 9.95 0.0024
Lama5 Laminin, alpha 5 1.34 8.74 0.0025
Col18a1 Collagen, type XVIII, alpha 1 0.91 9.65 0.0028
Ntn3 Netrin 3 1.22 6.42 0.0036
Prelp Proline arginine-rich end leucine-rich repeat 1.26 12.20 0.0039
Emilin2 Elastin microfibril interfacer 2 0.58 11.24 0.0041
Col6a2 Collagen, type VI, alpha 2 0.81 9.89 0.0045
Adamtsl1 ADAMTS-like 1 1.21 6.26 0.0055
Col6a1 Collagen, type VI, alpha 1 0.61 11.35 0.0057
Mfap2 Microfibrillar-associated protein 2 0.64 9.14 0.0065
Dpt Dermatopontin 1.15 6.55 0.0075
Ecm1 Extracellular matrix protein 1 0.52 12.72 0.0092
Npnt Nephronectin 1.33 7.47 0.0097
Spp1 Osteopontin 0.61 9.80 0.0106
Ogn Osteoglycin 0.69 10.46 0.0111
Lamb2 Laminin, beta 2 0.57 10.47 0.0115
Nid1 Nidogen 1 0.66 10.09 0.0115
Thsd4 Thrombospondin, type I, domain containing 4 1.01 5.17 0.0132
tgfbi Transforming growth factor, beta induced 0.77 6.83 0.0134
Spon2 Spondin 2, extracellular matrix protein 0.66 12.88 0.0138
Timp2 Tissue inhibitor of metalloproteinase 2 0.41 13.77 0.0165
Vcan Versican 0.64 7.64 0.0257
Fmod Fibromodulin 0.70 8.27 0.0325
Col16a1 Collagen, type XVI, alpha 1 0.31 11.82 0.0336
Tnxb Tenascin XB 0.76 6.75 0.0366
Vit Vitrin 0.63 6.10 0.0414
Tnc Tenascin C 0.30 11.17 0.0485
Lama1 Laminin, alpha 1 0.70 5.43 0.0490
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Table 1C Matrix metalloproteinase genes upregulated in supportive MSC.




Mmp3 Matrix metalloproteinase 3 4.15 8.32 0.0000
Mmp13 Matrix metalloproteinase 13 2.43 7.76 0.0001
Mmp10 Matrix metalloproteinase 10 2.41 6.66 0.0001
Cpxm1 Carboxypeptidase X 1 (M14 family) 1.80 9.09 0.0007
Adam33 A disintegrin and metalloproteinase domain 33 1.60 6.72 0.0007
Adam23 A disintegrin and metalloproteinase domain 23; similar to ADAM23 0.86 12.25 0.0024
Adamts1 A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 1 0.87 8.15 0.0058
Cpz Carboxypeptidase Z 0.96 5.06 0.0103
Adamts15 A disintegrin and metalloproteinase with thrombospondin type 1 motif, 15 0.80 5.62 0.0211
Mmp11 Matrix metalloproteinase 11 0.54 8.98 0.0279
Mmp24 Matrix metalloproteinase 24 0.47 9.47 0.0428
1231TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growthis consistent with previous findings in the bone marrow
suggesting that CD166 marks a population of lung stromal
cells with an increased propensity for myofibroblastic
differentiation (Battula et al., 2009; Buhring et al., 2009).
When injuries occur, tissue integrity is restored by the
contraction of myofibroblasts around the wound and the
deposition of new ECM forms the foundation for tissue
re-epithelialization (Duffield et al., 2012; Scotton and
Chambers, 2007). By virtue of these properties, myo-
fibroblasts are also considered to be the driving force behind
pulmonary fibrosis where their accumulation in the intersti-
tial space results in excess deposition of ECM that distorts
the architecture and function of the lung (Duffield et al.,
2013). However, despite the immense interest in their role
in pulmonary fibrosis, the cellular origin of myofibroblasts
is still a contentious issue. Historically, it has been widely
touted that myofibroblasts were derived from the trans-
differentiation of epithelial cells through a process known
as epithelial–mesenchymal transition (Willis and Borok,
2007). However, the recent identification of tissue resident
multipotent MSC has led us to reconsider the genesis of
myofibroblasts in solid organs (McQualter et al., 2009;
Summer et al., 2007; Lama et al., 2007; Mailleux et al.,
2005; Rock et al., 2011; Shan et al., 2008; Walker et al.,
2011). Lineage-tracing studies now suggest that myo-
fibroblasts are primarily derived from tissue resident MSC,
with little evidence of a direct lineage relationship between
epithelial cells and myofibroblasts in the adult lung (Rock
et al., 2011). Our data supports the concept that myo-
fibroblasts are derived from resident lung stromal cells that
differentiate into myofibroblasts in response to TGF-β.
Although the etiology of fibrosis is not well understood, it is
known that TGF-β is a key driver ofmyofibroblast differentiation
(Desmouliere et al., 1993; Sime et al., 1997; Thannickal et al.,
2003; Gu et al., 2007) and has been shown to stimulate ECM
secretion, increase contractility and activate pro-survival
signaling pathways (Horowitz et al., 2007; Gauldie et al.,
2006), all of which contribute to the perpetuation of fibrosis.
What is not known is how the classical TGF-β mediated
activation of lung stromal cells to a contractile,matrix-secreting
phenotype affects epithelial repair. In this study we demon-
strate that primary undifferentiated stromal cell progenitors act
as EpiSPC support cells, whereas their more differentiated
(α-SMApos) progeny do not. We also demonstrate that ex vivoexpansion of lung stromal cells results in the selective expansion
or induced differentiation of non-supportive stromal cells.
However, the epithelial-supportive capacity could be restored
by administration of a TGF-β receptor inhibitor (SB431542).
There was no change in the expression of the myofibroblast
differentiation marker αSMA between the epithelial-supportive
and non-supportive stromal cells in vitro. This suggests that the
epithelial-supportive capacity of lung stromal cells is regulated
by the stimulation or inhibition of TGF-β signaling rather than
differentiation alone. We also show that FGF-10 expression in
stromal cells was downregulated after classical activation with
TGF-β1 and upregulated after the inhibition of TGF-β with
SB431542. Thus, the epithelial-supportive capacity of lung
stromal cells is directly correlated with the level of FGF-10
expression.
In the developing lung, FGF-10 is elaborated by lung
stromal cells in the distal tip mesenchyme and is critical for
the process of branching morphogenesis during lung devel-
opment (Mailleux et al., 2005; Sekine et al., 1999; Min et al.,
1998; Park et al., 1998; Bellusci et al., 1997). We have also
previously shown that FGF-10 can partly replace the
requirement for lung stromal cell support in our CFU-Epi
assay (McQualter et al., 2010). More recently, it has also
been shown that FGF-10pos lung stromal cells are recruited
to the subepithelial space of naphthalene-injured airways
as part of the primary wound healing response (Volckaert
et al., 2011). The findings in this study support the idea
that FGF-10-expressing stromal cells are important media-
tors of EpiSPC-mediated repair in the adult lung.
Comparative gene expression analysis of ex vivo expand-
ed lung stromal cells also showed that the activation of an
epithelial-supportive phenotype was associated with the
reactivation of genes related to lung development, epithe-
lial morphogenesis and angiogenesis. This suggests that the
signaling pathways involved during lung development are
similar to those necessary for lung regeneration. In addition
to FGF-10, we observed an upregulation of growth factors
including pleiotrophin and midkine, which are thought to
be involved in lung development through the regulation of
epithelial cell proliferation and angiogenesis (Weng et al.,
2006, 2009; Reynolds et al., 2003, 2004). Together, these
studies suggest that classical TGF-β-mediated activation
of lung stromal cells suppresses their epithelial-supportive
capacity via the down regulation of epithelial-supportive
1232 J.L. McQualter et al.growth factors such as FGF-10, pleiotrophin and midkine.
The observed changes in the expression of genes encoding
extracellular matrix proteins and matrix metalloprotein-
ases also suggest that the epithelial supportive capacity
of lung stromal cell-mediated may be related to their
ability to change the composition of the extracellular
matrix to create a more permissive microenvironment for
epithelialization.
In summary, this study provides evidence that the
mesenchymal composition of the epithelial microenviron-
ment plays an important role in the regulation of epithelial
homeostasis. We propose a model in which resident lung
stromal cells are recruited to sites of epithelial injury to
promote re-epithelialization through the release of growth
factors, such as FGF-10, which promote the proliferation
of EpiSPC. Following re-epithelialization, the classical acti-
vation of differentiated stromal cells with TGF-β would
prevent excessive proliferation of EpiSPC via the down-
regulation of FGF-10 and other epithelial-supportive growth
factors. Our data also suggest that differentiated stromal
cells can be alternatively activated to an epithelial-
supportive phenotype via the inhibition of the TGF-β
pathway. The identification of different activation pathways
that promote epithelial-supportive versus non-supportive
lung stromal cell phenotypes provides new insight into the
mechanisms of wound healing in the lung. It also offers an
explanation to why fibroblastic foci in the lung are always
associated with diverse changes in the adjacent epithelium,
including epithelial denudation, senescence and hyperplasia
(Visscher and Myers, 2006; Misumi and Lynch, 2006; Qunn
et al., 2002; Kuhn et al., 1989; Kuhn and McDonald, 1991).
Activation of lung stromal cells towards an FGF-10pos
epithelial-supportive phenotype could enhance EpiSPC pro-
liferation after lung injury, while promotion of a non-
supportive phenotype could prevent uncontrolled EpiSPC
proliferation in epithelial hyperplasia and cancer. Further
understanding of the spatial and temporal diversity of lung
stromal cells in the lung and how they are activated to
promote or inhibit re-epithelialization will enhance our
ability to treat diseases that involve remodeling of the
stromal microenvironment.Acknowledgments
We thank Laura Failla and Huei Jiunn Seow (Lung Health Research
Centre, Australia) for their technical assistance with cell culture
studies and Real-Time PCR analysis, and Yifang Hu and Gordon
Smyth (The Walter and Eliza Hall Institute, Australia) for their
assistance in microarray data analysis. This study was supported by
grants from the Australian Stem Cell Centre (IB and JM), the
National Health and Medical Research Council (NHMRC) of Australia
(IB and JM Grant No. 1009374, RO Grant No. 1025239), a University
of Melbourne Early Career Research Fellowship (JM), an Australian
Research Council Queen Elizabeth II Fellowship (MA), and Victorian
State Government Operational Infrastructure Support and Australian
Government NHMRC IRIISS.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.08.007.References
Nyeng, P., Norgaard, G.A., Kobberup, S., Jensen, J., 2008. FGF10
maintains distal lung bud epithelium and excessive signaling
leads to progenitor state arrest, distalization, and goblet cell
metaplasia. BMC Dev. Biol. 8, 2.
Shannon, J.M., Nielsen, L.D., Gebb, S.A., Randell, S.H., 1998.
Mesenchyme specifies epithelial differentiation in reciprocal
recombinants of embryonic lung and trachea. Dev. Dyn. 212,
482–494.
El Agha, E., Al Alam, D., Carraro, G., MacKenzie, B., Goth, K., De
Langhe, S.P., Voswinckel, R., Hajihosseini, M.K., Rehan, V.K.,
Bellusci, S., 2012. Characterization of a novel fibroblast growth
factor 10 (Fgf10) knock-in mouse line to target mesenchymal
progenitors during embryonic development. PLoS One 7, e38452.
Warburton, D., Berberich, M.A., Driscoll, B., 2004. Stem/progenitor
cells in lung morphogenesis, repair, and regeneration. Curr. Top.
Dev. Biol. 64, 1–16.
Holgate, S.T., Davies, D.E., Lackie, P.M., Wilson, S.J., Puddicombe,
S.M., Lordan, J.L., 2000. Epithelial–mesenchymal interactions in
the pathogenesis of asthma. J. Allergy Clin. Immunol. 105, 193–204.
Volckaert, T., Dill, E., Campbell, A., Tiozzo, C., Majka, S., Bellusci,
S., De Langhe, S.P., 2011. Parabronchial smooth muscle
constitutes an airway epithelial stem cell niche in the mouse
lung after injury. J. Clin. Invest. 121, 4409–4419.
McQualter, J.L., Yuen, K., Williams, B., Bertoncello, I., 2010.
Evidence of an epithelial stem/progenitor cell hierarchy in the
adult mouse lung. Proc. Natl. Acad. Sci. U. S. A. 107, 1414–1419.
Teisanu, R.M., Chen, H., Matsumoto, K., McQualter, J.L., Potts, E.,
Foster, W.M., Bertoncello, I., Stripp, B.R., 2011. Functional
analysis of two distinct bronchiolar progenitors during lung injury
and repair. Am. J. Respir. Cell Mol. Biol. 44, 794–803.
McQualter, J.L., Brouard, N., Williams, B., Baird, B.N., Sims-Lucas,
S., Yuen, K., Nilsson, S.K., Simmons, P.J., Bertoncello, I., 2009.
Endogenous fibroblastic progenitor cells in the adult mouse lung
are highly enriched in the sca-1 positive cell fraction. Stem Cells
27, 623–633.
Summer, R., Fitzsimmons, K., Dwyer, D., Murphy, J., Fine, A., 2007.
Isolation of an adult mouse lung mesenchymal progenitor cell
population. Am. J. Respir. Cell Mol. Biol. 37, 152–159.
Martin, J., Helm, K., Ruegg, P., Varella-Garcia, M., Burnham, E.,
Majka, S., 2008. Adult lung side population cells have mesen-
chymal stem cell potential. Cytotherapy 10, 140–151.
Giangreco, A., Shen, H., Reynolds, S.D., Stripp, B.R., 2004.
Molecular phenotype of airway side population cells. Am.
J. Physiol. Lung Cell. Mol. Physiol. 286, L624–L630.
Hennrick, K.T., Keeton, A.G., Nanua, S., Kijek, T.G., Goldsmith,
A.M., Sajjan, U.S., Bentley, J.K., Lama, V.N., Moore, B.B.,
Schumacher, R.E., Thannickal, V.J., Hershenson, M.B., 2007.
Lung cells from neonates show a mesenchymal stem cell
phenotype. Am. J. Respir. Crit. Care 175, 1158–1164.
McCarty, R.C., Gronthos, S., Zannettino, A.C., Foster, B.K., Xian,
C.J., 2009. Characterisation and developmental potential of
ovine bone marrow derived mesenchymal stem cells. J. Cell.
Physiol. 219, 324–333.
Ritchie, M.E., Silver, J., Oshlack, A., Holmes, M., Diyagama, D.,
Holloway, A., Smyth, G.K., 2007. A comparison of background
correction methods for two-colour microarrays. Bioinformatics
23, 2700–2707.
Huang da, W., Sherman, B.T., Lempicki, R.A., 2009a. Systematic and
integrative analysis of large gene lists using DAVID bioinformatics
resources. Nat. Protoc. 4, 44–57.
Huang da, W., Sherman, B.T., Lempicki, R.A., 2009b. Bioinformatics
enrichment tools: paths toward the comprehensive functional
analysis of large gene lists. Nucleic Acids Res. 37, 1–13.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I.,
Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D.,
Horwitz, E., 2006. Minimal criteria for defining multipotent
1233TGF-β signaling in stromal cells acts upstream of FGF-10 to regulate epithelial stem cell growthmesenchymal stromal cells. The International Society for Cellular
Therapy position statement. Cytotherapy 8, 315–317.
Varisco, B.M., Ambalavanan, N., Whitsett, J.A., Hagood, J.S., 2012.
Thy-1 signals through PPARgamma to promote lipofibroblast
differentiation in the developing lung. Am. J. Respir. Cell Mol.
Biol. 46, 765–772.
Hinz, B., Phan, S.H., Thannickal, V.J., Galli, A., Bochaton-Piallat,
M.L., Gabbiani, G., 2007. The myofibroblast: one function,
multiple origins. Am. J. Pathol. 170, 1807–1816.
Hinz, B., Phan, S.H., Thannickal, V.J., Prunotto, M., Desmouliere,
A., Varga, J., De Wever, O., Mareel, M., Gabbiani, G., 2012.
Recent developments in myofibroblast biology: paradigms for
connective tissue remodeling. Am. J. Pathol. 180, 1340–1355.
Inman, G.J., Nicolas, F.J., Callahan, J.F., Harling, J.D., Gaster,
L.M., Reith, A.D., Laping, N.J., Hill, C.S., 2002. SB-431542 is a
potent and specific inhibitor of transforming growth factor-beta
superfamily type I activin receptor-like kinase (ALK) receptors
ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65–74.
Battula, V.L., Treml, S., Bareiss, P.M., Gieseke, F., Roelofs, H., de
Zwart, P., Muller, I., Schewe, B., Skutella, T., Fibbe, W.E.,
Kanz, L., Buhring, H.J., 2009. Isolation of functionally distinct
mesenchymal stem cell subsets using antibodies against CD56,
CD271, and mesenchymal stem cell antigen-1. Haematologica
Hematol. J. 94, 173–184.
Buhring, H.J., Treml, S., Cerabona, F., de Zwart, P., Kanz, L.,
Sobiesiak, M., 2009. Phenotypic characterization of distinct
human bone marrow-derived MSC subsets. Ann. N. Y. Acad. Sci.
1176, 124–134.
Duffield, J.S., Lupher, M., Thannickal, V.J., Wynn, T.A., 2013. Host
responses in tissue repair and fibrosis. Annu. Rev. Pathol. 8,
241–276.
Scotton, C.J., Chambers, R.C., 2007. Molecular targets in pulmo-
nary fibrosis: the myofibroblast in focus. Chest 132, 1311–1321.
Willis, B.C., Borok, Z., 2007. TGF-beta-induced EMT: mechanisms
and implications for fibrotic lung disease. Am. J. Physiol. Lung
Cell. Mol. Physiol. 293, L525–L534.
Lama, V.N., Smith, L., Badri, L., Flint, A., Andrei, A.C., Murray, S.,
Wang, Z., Liao, H., Toews, G.B., Krebsbach, P.H., Peters-
Golden, M., Pinsky, D.J., Martinez, F.J., Thannickal, V.J., 2007.
Evidence for tissue-resident mesenchymal stem cells in human
adult lung from studies of transplanted allografts. J. Clin. Invest.
117, 989–996.
Mailleux, A.A., Kelly, R., Veltmaat, J.M., De Langhe, S.P., Zaffran,
S., Thiery, J.P., Bellusci, S., 2005. Fgf10 expression identifies
parabronchial smooth muscle cell progenitors and is required for
their entry into the smooth muscle cell lineage. Development
132, 2157–2166.
Rock, J.R., Barkauskas, C.E., Cronce, M.J., Xue, Y., Harris, J.R.,
Liang, J., Noble, P.W., Hogan, B.L., 2011. Multiple stromal
populations contribute to pulmonary fibrosis without evidence
for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci.
U. S. A. 108, E1475–E1483.
Shan, L., Subramaniam, M., Emanuel, R.L., Degan, S., Johnston, P.,
Tefft, D., Warburton, D., Sunday, M.E., 2008. Centrifugal migration
of mesenchymal cells in embryonic lung. Dev. Dyn. 237, 750–757.
Walker, N., Badri, L., Wettlaufer, S., Flint, A., Sajjan, U.,
Krebsbach, P.H., Keshamouni, V.G., Peters-Golden, M., Lama,
V.N., 2011. Resident tissue-specific mesenchymal progenitor
cells contribute to fibrogenesis in human lung allografts. Am.
J. Pathol. 178, 2461–2469.
Desmouliere, A., Geinoz, A., Gabbiani, F., Gabbiani, G., 1993.
Transforming growth factor-beta 1 induces alpha-smooth muscle
actin expression in granulation tissue myofibroblasts and in quiescent
and growing cultured fibroblasts. J. Cell Biol. 122, 103–111.Sime, P.J., Xing, Z., Graham, F.L., Csaky, K.G., Gauldie, J., 1997.
Adenovector-mediated gene transfer of active transforming growth
factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin.
Invest. 100, 768–776.
Thannickal, V.J., Lee, D.Y., White, E.S., Cui, Z., Larios, J.M.,
Chacon, R., Horowitz, J.C., Day, R.M., Thomas, P.E., 2003.
Myofibroblast differentiation by transforming growth factor-
beta1 is dependent on cell adhesion and integrin signaling via
focal adhesion kinase. J. Biol. Chem. 278, 12384–12389.
Gu, L., Zhu, Y.J., Yang, X., Guo, Z.J., Xu, W.B., Tian, X.L., 2007.
Effect of TGF-beta/Smad signaling pathway on lung myo-
fibroblast differentiation. Acta Pharmacol. Sin. 28, 382–391.
Horowitz, J.C., Rogers, D.S., Sharma, V., Vittal, R., White, E.S., Cui,
Z., Thannickal, V.J., 2007. Combinatorial activation of FAK and
AKT by transforming growth factor-beta1 confers an anoikis-
resistant phenotype to myofibroblasts. Cell. Signal. 19, 761–771.
Gauldie, J., Kolb, M., Ask, K., Martin, G., Bonniaud, P., Warburton,
D., 2006. Smad3 signaling involved in pulmonary fibrosis and
emphysema. Proc. Am. Thorac. Soc. 3, 696–702.
Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato,
T., Yagishita, N., Matsui, D., Koga, Y., Itoh, N., Kato, S., 1999. Fgf10
is essential for limb and lung formation. Nat. Genet. 21, 138–141.
Min, H.S., Danilenko, D.M., Scully, S.A., Bolon, B., Ring, B.D., Tarpley,
J.E., DeRose, M., Simonet, W.S., 1998. Fgf-10 is required for both
limb and lung development and exhibits striking functional similarity
to Drosophila branchless. Genes Dev. 12, 3156–3161.
Park, W.Y., Miranda, B., Lebeche, D., Hashimoto, G., Cardoso,
W.V., 1998. FGF-10 is a chemotactic factor for distal epithelial
buds during lung development. Dev. Biol. 201, 125–134.
Bellusci, S., Grindley, J., Emoto, H., Itoh, N., Hogan, B.L., 1997.
Fibroblast growth factor 10 (FGF10) and branching morphogen-
esis in the embryonic mouse lung. Development 124, 4867–4878.
Weng, T., Chen, Z., Jin, N., Gao, L., Liu, L., 2006. Gene expression
profiling identifies regulatory pathways involved in the late
stage of rat fetal lung development. Am. J. Physiol. Lung Cell.
Mol. Physiol. 291, L1027–L1037.
Weng, T., Gao, L., Bhaskaran, M., Guo, Y., Gou, D., Narayanaperumal,
J., Chintagari, N.R., Zhang, K., Liu, L., 2009. Pleiotrophin
regulates lung epithelial cell proliferation and differentiation
during fetal lung development via beta-catenin and Dlk1. J. Biol.
Chem. 284, 28021–28032.
Reynolds, P.R., Mucenski, M.L., Le Cras, T.D., Nichols,W.C.,Whitsett,
J.A., 2004. Midkine is regulated by hypoxia and causes pulmonary
vascular remodeling. J. Biol. Chem. 279, 37124–37132.
Reynolds, P.R., Mucenski, M.L., Whitsett, J.A., 2003. Thyroid
transcription factor (TTF) -1 regulates the expression of midkine
(MK) during lung morphogenesis. Dev. Dyn. 227, 227–237.
Visscher, D.W., Myers, J.L., 2006. Histologic spectrum of idiopathic
interstitial pneumonias. Proc. Am. Thorac. Soc. 3, 322–329.
Misumi, S., Lynch, D.A., 2006. Idiopathic pulmonary fibrosis/usual
interstitial pneumonia: imaging diagnosis, spectrum of abnormali-
ties, and temporal progression. Proc. Am. Thorac. Soc. 3, 307–314.
Qunn, L., Takemura, T., Ikushima, S., Ando, T., Yanagawa, T.,
Akiyama, O., Oritsu, M., Tanaka, N., Kuroki, T., 2002. Hyperplastic
epithelial foci in honeycomb lesions in idiopathic pulmonary
fibrosis. Virchows Arch. 441, 271–278.
Kuhn 3rd, C., Boldt, J., King Jr., T.E., Crouch, E., Vartio, T.,
McDonald, J.A., 1989. An immunohistochemical study of archi-
tectural remodeling and connective tissue synthesis in pulmo-
nary fibrosis. Am. Rev. Respir. Dis. 140, 1693–1703.
Kuhn, C., McDonald, J.A., 1991. The roles of the myofibroblast in
idiopathic pulmonary fibrosis. Ultrastructural and immunohisto-
chemical features of sites of active extracellular matrix synthesis.
Am. J. Pathol. 138, 1257–1265.
